Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. A prospective study of 8 months duration in 64 patients with type-2 d...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2014-02, Vol.13 (1), p.49-49, Article 49
Main Authors: Rizzo, Manfredi, Chandalia, Manisha, Patti, Angelo Maria, Di Bartolo, Vittoria, Rizvi, Ali A, Montalto, Giuseppe, Abate, Nicola
Format: Article
Language:English
Subjects:
Aged
Atherosclerosis
Carotid Intima-Media Thickness
Cholesterol
Diabetes
Diabetes Mellitus, Type 2 - diagnostic imaging
Diabetes Mellitus, Type 2 - drug therapy
Drug dosages
Drug therapy
Female
Glucagon-Like Peptide 1 - analogs & derivatives
Glucagon-Like Peptide 1 - therapeutic use
Humans
Hypoglycemic Agents - therapeutic use
Liraglutide
Male
Methods
Middle Aged
Original Investigation
Pilot Projects
Prospective Studies
Statistical analysis
Studies
Triglycerides
Ultrasonic imaging
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound. After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p 
ISSN:1475-2840
1475-2840
DOI:10.1186/1475-2840-13-49